Steve Balt, MD
Research fellow, Addiction Pharmacology Research Laboratory, California Pacific Medical Center
Dr. Balt discloses that his spouse is employed as a sales representative for Bristol Myers Squibb.
Patients are probably asking you about Deplin, or L-methylfolate, a version of folic acid that is being marketed by Pamlab as an adjunctive treatment for depression.
Steve Balt, MD
Research fellow, Addiction Pharmacology Research Laboratory, California Pacific Medical Center
Dr. Balt discloses that his spouse is employed as a sales representative for Bristol Myers Squibb.
Daniel Carlat, MD
Editor-in-Chief, Publisher, The Carlat Report.
Dr. Carlat has disclosed that he has no relevant relationships or financial interests in any commercial company pertaining to this educational activity.
Nuedexta is a combination of dextromethorphan (DM) and quinidine sulfate. You might reasonably ask why these two agents would have ever been considered as a treatment for PBA.
Marlene Freeman, MD
Associate professor of psychiatry, Harvard Medical School, Director of clinical services, Perinatal and Reproductive Psychiatry Clinical Research Program, Massachusetts General Hospital
Dr. Freeman has received research support from Lilly, GlaxoSmithKline, and Forest Pharmaceuticals for the study of duloxetine, Lovaza (omega-3 fatty acid), and escitalopram. She has also served as a consultant to Bristol Myers Squibb on measurement based care. Dr. Carlat has reviewed this article and found no evidence of bias in this educational activity.
Defining CAM is challenging. One of the things that makes it so hard to have a concrete discussion on CAM is that it means different things to different people.
Glen Spielmans, PhD
Associate professor of psychology, Metropolitan State University, St. Paul, MN
Glen Spielmans, PhD, has disclosed that he has no relevant financial or other interests in any commercial companies pertaining to this educational activity.
Common sense dictates that genetic predispositions probably interact with life stressors to influence our mental health. Plenty of research has been published to evaluate whether this is actually true, but findings have been mixed.
Glen Spielmans, PhD
Associate professor of psychology, Metropolitan State University, St. Paul, MN
Glen Spielmans, PhD, has disclosed that he has no relevant financial or other interests in any commercial companies pertaining to this educational activity.
Whether you see your patients quarterly, monthly, or even weekly, you certainly are not with them as much as their cell phones are.
There are a lot of electronic health record (EHR—also called electronic medical record, or EMR) companies vying for your hard earned cash. How do you decide among them?
Most of you have probably heard about “meaningful use” and federal incentives to get going with an electronic health record. But how applicable is this for psychiatrists? And what in the world is “meaningful use” anyway?
The charge of this committee is to follow developments in electronic health record issues—more related to policy than to technology—and to serve as a resource for members and for other councils and committees of the APA.